<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01255891</url>
  </required_header>
  <id_info>
    <org_study_id>McG 0913</org_study_id>
    <nct_id>NCT01255891</nct_id>
  </id_info>
  <brief_title>Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate</brief_title>
  <official_title>A Phase II Study of Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>McGill University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of LHRH agonist with adjuvant pelvic radiation therapy in post&#xD;
      radical prostatectomy patients with high risk pathological features for failure. To determine&#xD;
      the freedom from biochemical (maintenance of a PSA less than nadir + 2 ng/ml) and clinical&#xD;
      progression rate at 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Same as brief Summary&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to determine the rate of local and distance failure at 5 years</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Adenocarcinoma of the Prostate</condition>
  <arm_group>
    <arm_group_label>Adjuvant</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adjuvant suppression plus radiation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Androgen suppression plus radiation therapy</intervention_name>
    <description>Adjuvant androgen suppression plus radiation therapy</description>
    <arm_group_label>Adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adenocarcinoma of the prostate treated primarily with radical prostatectomy,&#xD;
             pathologically proven to be lymph node negative by pelvic lymphadenectomy (N0) or&#xD;
             lymph node status pathologically unknown (undissected pelvic lymph nodes [Nx]), i.e.&#xD;
             lymph node dissection is not required;&#xD;
&#xD;
          2. Any type of radical prostatectomy will be permitted, including retropubic, perineal&#xD;
             laparoscopic or robotically assisted. If performed, the number of lymph nodes removed&#xD;
             per side of the pelvis and the extent of the pelvic lymph node dissection (obturator&#xD;
             vs. extended lymph node dissection) should be noted. There is no time limit for the&#xD;
             date of radical prostatectomy.&#xD;
&#xD;
          3. A post-radical prostatectomy entry PSA of &gt; 0 and &lt; 1 ng/ml at least 6 weeks after&#xD;
             prostatectomy and within 30 days of registration.&#xD;
&#xD;
          4. One of the following pathologic/chemical classifications:&#xD;
&#xD;
               -  T3N0/Nx disease with or without positive surgical margin; or;&#xD;
&#xD;
               -  Gleason score of 8 or more;&#xD;
&#xD;
               -  Pre prostatectomy PSA &gt; 20 ng/ml&#xD;
&#xD;
          5. KPS &gt; 70&#xD;
&#xD;
          6. Age ≥ 18;&#xD;
&#xD;
          7. No distant metastases, based upon the following minimum diagnostic workup:&#xD;
&#xD;
          8. History/physical examination (including digital rectal exam) within 8 wks prior to&#xD;
             registration;&#xD;
&#xD;
          9. A CT scan or MRI of the abdomen and pelvis within 120 days prior to registration;&#xD;
&#xD;
         10. Bone scan within 120 days prior to registration; if the bone scan is suspicious, a&#xD;
             plain x-ray and/or MRI must be obtained to rule out metastasis.&#xD;
&#xD;
         11. Adequate bone marrow function, within 90 days prior to registration, defined as&#xD;
             follows:&#xD;
&#xD;
               -  Platelets ≥ 100,000 cells/mm3 based upon CBC;&#xD;
&#xD;
               -  Hemoglobin ≥ 10.0 g/dl based upon CBC&#xD;
&#xD;
               -  AST or ALT &lt; 2 x the upper limit of normal within 90 days prior to registration;&#xD;
&#xD;
         12. Patients must sign a study-specific informed consent prior to study entry.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. A palpable prostatic fossa abnormality/mass suggestive of recurrence, unless shown by&#xD;
             biopsy under ultrasound guidance not to contain cancer;&#xD;
&#xD;
          2. N1 patients are ineligible, as are those with pelvic lymph node enlargement ≥ 1.5 cm&#xD;
             in greatest dimension by CT scan or MRI of the pelvis, unless the enlarged lymph node&#xD;
             is sampled and is negative;&#xD;
&#xD;
          3. Androgen deprivation therapy started prior to prostatectomy for &gt; 6 months duration;&#xD;
&#xD;
          4. Androgen deprivation therapy started after prostatectomy and prior to registration;&#xD;
&#xD;
          5. Prior pelvic radiotherapy;&#xD;
&#xD;
          6. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free&#xD;
             for a minimum of 5 years (for example, carcinoma in situ of the oral cavity is&#xD;
             permissible);&#xD;
&#xD;
          7. Severe, active co-morbidity, defined as follows:&#xD;
&#xD;
               -  History of inflammatory bowel disease;&#xD;
&#xD;
               -  History of hepatitis B or C; Blood tests are not required to determine if the&#xD;
                  patient has had hepatitis B or C, unless the patient reports a history of&#xD;
                  hepatitis.&#xD;
&#xD;
               -  Unstable angina and/or congestive heart failure requiring hospitalization within&#xD;
                  the last 6 months;&#xD;
&#xD;
               -  Transmural myocardial infarction within the last 6 months&#xD;
&#xD;
               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time&#xD;
                  of registration;&#xD;
&#xD;
               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness&#xD;
                  requiring hospitalization or precluding study therapy at the time of&#xD;
                  registration;&#xD;
&#xD;
               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;&#xD;
                  AST or ALT are required; note, however, that laboratory tests for coagulation&#xD;
                  parameters are not required for entry into this protocol.&#xD;
&#xD;
               -  Prior allergic reaction to the study drug(s) involved in this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamim Niazi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Department of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tamim Niazi, Dr.</last_name>
    <phone>514-340-8248</phone>
    <email>tamim.niazi@mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Souhami, MD</last_name>
      <phone>514-934-8040</phone>
      <email>luis.souhami@muhc.mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Audrey Fernandes, Ph.D.</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>43128</phone_ext>
      <email>audrey.fernandes@muhc.mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Luis Souhami, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Fournier, Ph.D.</last_name>
      <phone>514-340-8248</phone>
      <email>bfournier@jgh.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Tamim Niazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.crp.mcgill.ca</url>
    <description>Research page</description>
  </link>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>December 7, 2010</study_first_submitted>
  <study_first_submitted_qc>December 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2010</study_first_posted>
  <last_update_submitted>December 7, 2010</last_update_submitted>
  <last_update_submitted_qc>December 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tamim Niazi, Principal Investigator</name_title>
    <organization>McGill University Department of Oncology</organization>
  </responsible_party>
  <keyword>high risk localized adenocarcinoma of the prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

